Fluorouracil and the New Oral Fluorinated Pyrimidines
OBJECTIVE:
To briefly review the biotransformation and bioavailability of fluorouracil (5-FU); discuss the effects of dihydropyrimidine dehydrogenase (DpD) on the efficacy and toxicity profiles of 5-FU; and review a new class of drugs known collectively as the oral fluorinated pyrimidines, which inhibit or circumvent DpD activity and, when administered with 5-FU, alter its pharmacokinetic and pharmacodynamic properties.
DATA SOURCES:
A MEDLINE literature search was conducted (1966–March 1999), using the search terms fluoropyrimidines, fluorouracil, 5-FU, fluorinated pyrimidines, capecitabine, eniluracil, uraciltegafur, uracilftorafur, UFT, S1, BMS-247616, and BOF-A2. Reference lists, bibliographies of pertinent articles, and abstracts from the American Society of Clinical Oncology and the San Antonio Breast Cancer Symposium annual meetings were also identified and reviewed. Both preclinical and clinical literature were reviewed and analyzed.
DATA SYNTHESIS:
The new oral fluorinated pyrimidines appear to produce antitumor activity equivalent or superior to that of intravenously administered 5-FU by achieving higher intratumoral 5-FU concentrations or sustained 5-FU exposure. These agents are generally associated with manageable and non-life—threatening toxicities. The oral route of administration facilitates ease of administration and may reduce total healthcare costs associated with 5-FU—sensitive tumors. More studies are needed to assess the therapeutic and economic benefits of the oral fluorinated pyrimidines.
CONCLUSIONS:
The bioavailability, efficacy, and toxicity of 5-FU depend on its catabolic rate—limiting enzyme, DpD. The new oral fluorinated pyrimidines inhibit or circumvent DpD activity and, when combined with 5-FU, increase 5-FU's bioavailability and cytotoxic effects and decrease its toxicities. Results of Phase I and II studies in patients with a variety of malignancies suggest positive outcomes, including greater efficacy, less drug-related toxicity, lower costs related to drug administration, and greater patient convenience.
Топ-30
Журналы
|
1
2
3
|
|
|
Oncologist
3 публикации, 7.5%
|
|
|
Cancer Letters
2 публикации, 5%
|
|
|
Bioorganic and Medicinal Chemistry Letters
2 публикации, 5%
|
|
|
European Journal of Cancer
1 публикация, 2.5%
|
|
|
Nuclear Medicine and Biology
1 публикация, 2.5%
|
|
|
Cancer Nursing
1 публикация, 2.5%
|
|
|
World Journal of Gastrointestinal Oncology
1 публикация, 2.5%
|
|
|
Toxicologic Pathology
1 публикация, 2.5%
|
|
|
Journal of International Medical Research
1 публикация, 2.5%
|
|
|
Pharmaceutics
1 публикация, 2.5%
|
|
|
Scientific Reports
1 публикация, 2.5%
|
|
|
Inpharma Weekly
1 публикация, 2.5%
|
|
|
Reactions Weekly
1 публикация, 2.5%
|
|
|
Pharmacogenomics Journal
1 публикация, 2.5%
|
|
|
Journal of Cancer Research and Clinical Oncology
1 публикация, 2.5%
|
|
|
International Journal of Colorectal Disease
1 публикация, 2.5%
|
|
|
BioDrugs
1 публикация, 2.5%
|
|
|
Cell Biochemistry and Biophysics
1 публикация, 2.5%
|
|
|
Biochemical Genetics
1 публикация, 2.5%
|
|
|
Molecular Cancer
1 публикация, 2.5%
|
|
|
European Journal of Medicinal Chemistry
1 публикация, 2.5%
|
|
|
ChemBioChem
1 публикация, 2.5%
|
|
|
Colorectal Disease
1 публикация, 2.5%
|
|
|
Organic Preparations and Procedures International
1 публикация, 2.5%
|
|
|
Journal of the National Cancer Institute
1 публикация, 2.5%
|
|
|
Journal of Amino Acids
1 публикация, 2.5%
|
|
|
Journal of Clinical Oncology
1 публикация, 2.5%
|
|
|
Side Effects of Drugs Annual
1 публикация, 2.5%
|
|
|
Synthesis
1 публикация, 2.5%
|
|
|
1
2
3
|
Издатели
|
2
4
6
8
10
|
|
|
Springer Nature
10 публикаций, 25%
|
|
|
Elsevier
9 публикаций, 22.5%
|
|
|
Wiley
4 публикации, 10%
|
|
|
Society for Translational Oncology
3 публикации, 7.5%
|
|
|
SAGE
2 публикации, 5%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 публикация, 2.5%
|
|
|
Baishideng Publishing Group
1 публикация, 2.5%
|
|
|
MDPI
1 публикация, 2.5%
|
|
|
Taylor & Francis
1 публикация, 2.5%
|
|
|
Oxford University Press
1 публикация, 2.5%
|
|
|
Hindawi Limited
1 публикация, 2.5%
|
|
|
American Society of Clinical Oncology (ASCO)
1 публикация, 2.5%
|
|
|
Georg Thieme Verlag KG
1 публикация, 2.5%
|
|
|
BMJ
1 публикация, 2.5%
|
|
|
2
4
6
8
10
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.